New PET scan agent aims to spot HER2 cancers more safely

NCT ID NCT04692831

Ongoing Diagnosis Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This phase 1 trial tests whether a new radioactive imaging agent, 89Zr-ss-pertuzumab, is safe for detecting HER2-positive breast cancer in 60 participants. The agent is designed to bind to HER2 proteins on cancer cells and show up on PET/CT scans. The main goal is to check for side effects, not yet to measure how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 89Zr-ss-pertuzumab (a radioactive imaging agent)
What this could lead to: If successful, this could provide a safer and more precise way to detect HER2-positive cancers using PET/CT scans, helping guide treatment decisions.
What could go wrong: This is an early phase 1 trial focused on safety, not effectiveness. The imaging agent may not work as expected, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER-2 POSITIVE MALIGNANT CARCINOMA OF BREAST are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER-2 POSITIVE MALIGNANT CARCINOMA OF BREAST HER-2 PROTEIN OVEREXPRESSION HER2-POSITIVE METASTATIC BREAST CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (Limited protocol activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activites)

Rockville Centre, New York, 11553, United States
Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity)

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.